Develops and commercializes molecular testing services globally. Offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 39% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 4 years, sales grew about 39% a year on average.
The company sells $2.3B a year; the problem isn’t sales — it’s costs running above that number.
There is $1.1B in the vault; even if every debt were paid off, $861.8M would remain.
A loss of $208.2M against $2.3B in annual sales.
Over the last 12 months, executives reported 341 sells against just 68 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, NTRA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NTRA has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.